Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) combination therapy (EAP regimen) in mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma (NHL). A total of 99 NHL patients will be enrolled as research subjects and will be randomly allocated in a 2:1 ratio to compare the EAP regimen versus disease-specific chemotherapy mobilization regimen. The primary endpoint is the proportion of patients achieving the ideal collection value after a single collection (CD34+ cells ≥5×10\^6/kg).
Phase:
PHASE3
Details
Lead Sponsor:
The Affiliated People's Hospital of Ningbo University
Collaborators:
Affiliated Hospital of Jiaxing University Dongyang People's Hospital First Affiliated Hospital of Wenzhou Medical University First Affiliated Hospital of Zhejiang University Huizhou Municipal Central Hospital Jinhua Municipal Central Hospital Jinhua People's Hospital Ningbo Medical Center Lihuili Hospital Second Affiliated Hospital of Wenzhou Medical University Shaoxing People's Hospital Shaoxing Second Hospital Taizhou Hospital Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University The Central Hospital of Lishui City Zhejiang Provincial Tongde Hospital